FoundationOne™ Test Registry Study

Cancer Clinical Trial

— FMI Registry  

Official title:

A Prospective Observational Study to Examine, in Routine Clinical Practice in the US, Practice Patterns and Impact on Clinical Decision Making Associated With the FoundationOne™ Next Generation Sequencing (NGS) Test

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT01851213
• Other study ID #: FMI-001-NGS-500
• Status: Completed
• Phase: N/A
• First received: May 6, 2013
• Last updated: August 8, 2016
• Start date: March 2013
• Est. completion date: March 2016

Study information

• Verified date: August 2016
• Source: Foundation Medicine
• Contact: n/a
• Is FDA regulated: No
• Health authority: United States: Institutional Review Board
• Study type: Observational [Patient Registry]

Clinical Trial Summary

This study is a prospective, multicenter, observational study to characterize utilization patterns of the FoundationOne™ test by oncologists under conditions of routine clinical practice in the US. The study will also examine impact of test results on subsequent clinical decisions regarding choice of therapy. The planned duration of the study is at least 2 years with 1 year for patient recruitment and a minimum 1-year follow-up period for each patient. Any patient for whom the treating physician has ordered a FoundationOne™ test and a report is delivered is eligible for participation on the study. Eligible patients from participating sites will be enrolled sequentially during the 1-year enrollment period. Sites will be required to maintain an enrollment log of all patients for whom the FoundationOne™ test has been ordered and document patient disposition and reasons for non-participation. All treatment decisions and clinical assessment will be made at the discretion of the treating physician per usual care and are not mandated by study design or protocol. Informed consent will be obtained from eligible patients prior to study entry.

Description:

Molecular testing of tumors, using techniques such as next-generation sequencing (NGS), facilitates an individualized approach to cancer treatment by sub-classifying diseases on an individual basis. Physicians can utilize an in depth understanding of disease at a molecular level to optimize therapy by selecting the most appropriate drugs and therapeutic targets. Genomic profiling has identified multiple genomic aberrations that are predictive markers for treatment response with targeted therapeutics.

FoundationOne™ is a commercially available molecular diagnostics test, for all solid tumor types, that analyzes routine clinical specimens for somatic alterations in relevant cancer-related genes. This validated in vitro diagnostic test, is performed in a single Clinical Laboratory Improvement Amendments (CLIA) certified and College of American Pathologists (CAP) approved laboratory at Foundation Medicine, Inc. It provides individualized, potentially actionable information regarding a patient's molecular cancer subtype that can be used by physicians to tailor treatment options.

With the recent commercial availability of the FoundationOne™ test, knowledge gaps exist regarding practice patterns associated with the use of this test in routine clinical practice and the impact of this test on clinical decision making. There is limited information regarding physician and patient characteristics that determine which patients receive the test, rationale for patient selection, and how physicians interpret and use the test results. Findings from this study will help to optimize patient selection and maximize the clinical impact of the test in terms of guiding therapy.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 510
• Est. completion date: March 2016
• Est. primary completion date: January 2016
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

The FoundationOne test was ordered by the treating physician under routine clinical practice

• Age = 18 years

• Patient willing and able to provide informed consent

• Informed consent date is at least one day prior to the FoundationOne test report date

Exclusion Criteria:

There are no exclusion criteria for this study

Study Design

Observational Model: Cohort, Time Perspective: Prospective

Related Conditions & MeSH terms

• Cancer
• Neoplasm Metastasis
• Tumor

Locations

Country	Name	City	State
United States	Evergreen Hematology/Oncology	Spokane	Washington

Sponsors (2)

Lead Sponsor	Collaborator
Foundation Medicine	Quintiles, Inc.

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Composite characterization of current real-world practice patterns in the use of the FoundationOne™ test and the effect of the FoundationOne™ test on clinical decision making across the US	Characterization of practice patterns for the use of the test described by: Provider and site characteristics of patients receiving the FoundationOne test; Socio-demographic and clinical characteristics of patients receiving the FoundationOne test; Examination of the effect of the test on clinical decision making by describing: Subsequent treatment patterns for patients after receipt of test results; Clinician report outcomes regarding how test results guided clinical decision making	Minimum 1 year follow-up	No
Secondary	Exploratory endpoints describing clinical outcomes in the study population	Overall survival; 1-year survival; Overall progression-free survival (PFS)	Minimum 1 year follow-up	No